Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07059000 · ClinicalTrials.gov registry record · Phase 3
A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)
A Phase 3 study of Chronic Primary Immune Thrombocytopenia (ITP), sponsored by Kedrion S.p.A..
- Recruiting
- Registry status
- Phase 3
- Development phase
- 40
- Enrollment target
- 20
- Study locations
NCT07059000 is a Phase 3 study of Chronic Primary Immune Thrombocytopenia (ITP) that is actively recruiting participants, run by Kedrion S.p.A.. The registered enrollment target is 40 participants. The trial reports 20 study locations across 18 states.
The verdict
NCT07059000, a Phase 3 study of Chronic Primary Immune Thrombocytopenia (ITP), is actively recruiting participants, sponsored by Kedrion S.p.A..
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 40 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of KIg 10 (Intravenous Immunoglobulin 10%) in adult patients with chronic primary ITP
Conditions Studied
Interventions
- BIOLOGICAL Kedrion IVIG 10%
Study Locations (20)
Other
- Univerzitetski Klinicki Centar Srbije - Belgrade
- Klinicko-Bolnicki Centar Zemun - Belgrade
Madrid
- Complejo Hospitalario Ruber Juan Bravo - Madrid
- Hospital General Universitario Gregorio Marañón - Madrid
California
- University of Southern California - Los Angeles
North Carolina
- East Carolina University - Greenville
Prague
- Vseobecna Fakultni Nemocnice v Praze - Prague
South Moravian
- Fakultni Nemocnice Brno - Brno
Bavaria
- Onkologisches Zentrum Donauwörth Neudegger - Onkomedeor Onkologische Zentren - Donauwörth
Hesse
- Universitätsklinikum Frankfurt - Frankfurt am Main
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-08-13 |
| Est. Completion | 2026-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07059000
The ClinicalTrials.gov registry entry for NCT07059000 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kedrion S.p.A., which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Primary Immune Thrombocytopenia (ITP) appearing as the primary indexed condition, and to 1 intervention - of which Kedrion IVIG 10% is the first listed.
NCT07059000 reports 20 study locations spanning 18 distinct geographic areas - top geographies include Other, Madrid, California.
Frequently Asked Questions
What is clinical trial NCT07059000 about?
NCT07059000 is a clinical study titled "A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)". The purpose of this study is to evaluate the efficacy and safety of KIg 10 (Intravenous Immunoglobulin 10%) in adult patients with chronic primary ITP
What is the current status of trial NCT07059000?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 40 participants. The study started on 2025-08-13. Estimated completion is 2026-08.
What conditions does trial NCT07059000 study?
This clinical trial studies the following conditions: Chronic Primary Immune Thrombocytopenia (ITP).
What interventions are being tested in trial NCT07059000?
The interventions under investigation include: Kedrion IVIG 10% (BIOLOGICAL).
Who is sponsoring clinical trial NCT07059000?
This trial is sponsored by Kedrion S.p.A., which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07059000 being conducted?
This trial has 20 study locations across California, North Carolina, Prague, South Moravian, Bavaria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.